Merck KGaA (OTCMKTS:MKKGY) Cut to Hold at Zacks Research

Merck KGaA (OTCMKTS:MKKGY – Get Free Report) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Thursday,Zacks.com reports.

Several other equities research analysts also recently commented on the stock. HSBC raised shares of Merck KGaA to a “hold” rating in a research report on Monday, July 6th. UBS Group downgraded Merck KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Finally, Jefferies Financial Group began coverage on Merck KGaA in a report on Tuesday, May 26th. They set a “hold” rating for the company. Six investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, Merck KGaA currently has a consensus rating of “Hold”.

Get Merck KGaA alerts:

View Our Latest Report on Merck KGaA

Merck KGaA Stock Up 0.6%

Merck KGaA stock opened at $32.24 on Thursday. Merck KGaA has a 1-year low of $23.73 and a 1-year high of $34.19. The firm has a market capitalization of $20.83 billion, a price-to-earnings ratio of 16.62, a price-to-earnings-growth ratio of 2.62 and a beta of 0.98. The firm’s fifty day moving average price is $32.23 and its two-hundred day moving average price is $29.36. The company has a current ratio of 1.51, a quick ratio of 1.00 and a debt-to-equity ratio of 0.36.

Merck KGaA Company Profile

(Get Free Report)

Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.

Featured Stories

• Five stocks we like better than Merck KGaA
• Blueprint for a Boom: SEC Clears the Crypto Runway
• Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
• Advance Auto Parts Plunged, But Its Turnaround Is Still Working
• Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.